Citius Oncology Reports Increased Net Loss and Prepares for LYMPHIR Launch

Citius Oncology, Inc. reported its financial results for the third quarter and nine months ended June 30, 2025, revealing a net loss of $5.37 million for the quarter and $19.76 million for the nine-month period. This represents an increase in net loss compared to $4.77 million and $14.34 million for the same periods in 2024, respectively. The company did not generate any revenue during these periods, maintaining a consistent trend from the previous year. Operating expenses for the quarter totaled $4.94 million, slightly higher than the $4.63 million reported in the prior year, primarily due to increased general and administrative costs associated with the pre-commercialization activities for its product, LYMPHIR.

Citius Oncology's total assets increased to $91.71 million as of June 30, 2025, up from $84.37 million at the end of the previous fiscal year. This growth was driven by a significant rise in inventory, which reached $17.21 million, compared to $8.27 million in September 2024. However, the company also saw a substantial increase in current liabilities, which rose to $52.99 million from $32.70 million, largely due to increased accounts payable and accrued expenses. The accumulated deficit now stands at $59.04 million, reflecting the ongoing financial challenges faced by the company.

Strategically, Citius Oncology is preparing for the commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma, which is expected to begin in the second half of 2025. The company has entered into distribution agreements with Cardinal Health and Cencora to facilitate the product's market entry. Additionally, Citius Oncology has been actively engaged in capital raising efforts, including a public offering completed on July 17, 2025, which generated approximately $9 million in gross proceeds. This funding is crucial as the company anticipates needing additional capital to support operations beyond September 2025.

Operationally, Citius Oncology has not reported any significant changes in customer counts or user statistics, as it has yet to generate revenue. The company continues to rely heavily on funding from its parent company, Citius Pharma, which has provided financial support through various means, including a promissory note. As of June 30, 2025, Citius Oncology had only $112 in cash, highlighting the urgent need for additional financing to meet its obligations, including milestone payments to Dr. Reddy's and Eisai, as well as commitments under manufacturing agreements.

Looking ahead, Citius Oncology's management has expressed optimism about the potential for LYMPHIR to generate revenue, but acknowledges the substantial risks involved, including the need for ongoing funding and the successful execution of its commercialization strategy. The company has retained Jefferies LLC as its financial advisor to explore strategic alternatives aimed at maximizing shareholder value. However, there remains significant uncertainty regarding the company's ability to continue as a going concern, as it must secure additional capital to sustain operations beyond the near term.